Evaluation of brain glutamatergic mechanisms in... — Clinical Trial Details

Low-dose ketamine has fast-acting positive effects on mood in patients with treatment resistant anxiety, similar to its effects in depression. This is a mechanistic study to assess changes in brain function in patients with treatment resistant anxiety treated with ketamine or a psychoactive control, using a range of assessment methods (brain imaging, EEG analysis, blood pharmacokinetic samples). Data from this study may help clarify the neurobiological basis of treatment-resistant anxiety.

Male or female aged 18-65y
Diagnosed with DSM-5 Generalized Anxiety Disorder and/or Social Anxiety Disorder, with inadequate response to prior treatment i.e. unsuccessful with 1 or more prescribed antidepressants and prior failed psychotherapy
Hamilton Anxiety Scale (HAM-A) score of >20, and/or a Liebowitz Social Anxiety Scale (LSAS) score of >60 at screening.

evidence of severe acute or chronic medical disorders,
presence of implanted cardiac pacemakers, hearing aids, insulin pumps or neurostimulators; intracranial metal clips; or metallic bodies in the eye
past or current diagnoses of schizophrenia, bipolar disorder, or current psychotic symptoms
female patients who are pregnant or lactating
drug abuse or dependence in the last 6 months
current significant suicidal ideation
current Major Depressive Disorder (MADRS >20 at screening).
participants must be free of recreational drug and alcohol use at the time of testing

Company

Product

Legal

Evaluation of brain glutamatergic mechanisms in patients with treatment resistant anxiety - comparative effects of ketamine vs fentanyl

Detailed Description

Study Arms & Interventions

Experimental Arm

Interventions

Participants

Inclusion Criteria

Locations

Exclusion Criteria

Study Details